COVID-19 and Endocrine and Metabolic Diseases: An Updated Statement from the European Society of Endocrinology

May 2021 in “ Endocrine ”

Manel Puig-Domingo, Mónica Marazuela, Bülent O. Yildiz, Andrea Giustina

diabetes obesity glycemic control metformin statins hypocalcemia vitamin D deficiency blood sugar control glucophage lipitor low calcium vitamin D

From the encyclopedia

Metformin →

diabetes drug with anti-inflammatory, immunomodulatory, and insulin-sensitizing properties

Vitamin D →

vitamin you should probably be taking for general health might also help your hair a little

Studysummary This review discusses the emerging "endocrine phenotype" of COVID-19, highlighting the implications for managing diabetes, obesity, vitamin D deficiency, and other endocrine conditions in affected patients.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer

View this study on link.springer.com →

Discuss this study in the Community →

Research cited in this study

5 / 5 results

Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial

research Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial

41 citations , February 2021 in “Cureus”

In this study, Proxalutamide significantly increased the rate of viral clearance and reduced clinical remission time in patients with mild to moderate COVID-19 compared to placebo.

Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial

research Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial

41 citations , February 2021 in “Cureus”

This study found that in males with mild COVID-19, treatment with dutasteride, along with standard therapy, may reduce viral shedding and inflammation compared to placebo.

An Assessment on the Impact of COVID-19 Infection in a Gender-Specific Manner

COVID-19 and Endocrine and Metabolic Diseases: An Updated Statement from the European Society of Endocrinology

Research cited in this study

research Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial

research Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial

research An Assessment on the Impact of COVID-19 Infection in a Gender-Specific Manner

research Male Balding Is a Major Risk Factor for Severe COVID-19

research Androgenetic Alopecia Present in the Majority of Patients Hospitalized with COVID-19: The 'Gabrin Sign'